Ace the ACRN Challenge 2025 – Boost Your Nursing Superpowers!

The most appropriate prophylaxis for Pneumocystis jiroveci pneumonia (PJP) in patients with AIDS is typically to use a medication such as trimethoprim-sulfamethoxazole (TMP-SMX). Individuals with a CD4 count below 200 cells/mm³ are at a high risk for PJP, so initiating prophylaxis becomes critical to prevent this opportunistic infection.

Selecting prophylaxis that addresses multiple potential infections common in immunocompromised patients, such as both Pneumocystis jiroveci and toxoplasmosis, is a comprehensive approach. Toxoplasmosis prophylaxis is indicated for patients with a CD4 count below 100 cells/mm³ and who have positive IgG for Toxoplasma gondii. By addressing both conditions, the prophylactic strategy ensures better protection against these severe opportunistic infections, which are prevalent in individuals with AIDS and low immune function.

In other scenarios where prophylaxis options are provided separately, the choice of addressing multiple infections aligns with best practices in managing the risk of opportunistic diseases in this high-risk population. Thus, this holistic approach in prophylaxis enhances patient outcomes and prevents hospitalizations due to opportunistic infections.